This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) and Exelixis also recently revealed new analyses from a phase 3 study of their Opdivo (nivolumab) and Cabometyx (cabozantinib) combination in first-line, advanced RCC. ... BMS/Exelixis’ combination treatment doubled median
BMS/Exelixis’ combination treatment doubled median PFS compared to Sutent, and also demonstrated a 34% reduction in the risk of death compared to Pfizer’s drug. ... BMS and Exelixis are also seeking approvals with additional health authorities
The US Food and Drug Administration (FDA) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Exelixis’ Cabometyx in renal cell carcinoma (RCC) – the most common type of ... The European Medicines Agency (EMA) has already
and Exelixis’ tyrosine kinase inhibitor Cabometyx (cabozantinib).
Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... BMS and Exelixis have already completed their
ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of trial failures, while GlaxoSmithKline/Exelixis’ also seem to have dropped their MET/VEGF inhibitor foretinib and
More from news
Approximately 6 fully matching, plus 26 partially matching documents found.
Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.
Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
He joins the biotech as its vice president, strategy. California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy. ... His familiarity with Exelixis and the biotech landscape should make for a seamless
Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological
Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...